Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Gastritis II: Pathophysiology

Gastritis II: Pathophysiology

The pathophysiology of gastritis begins with the colonization of the stomach lining by Helicobacter pylori (H. pylori). This bacterium spreads mainly via the oral-oral route through saliva or shared utensils, and can also be transmitted in overcrowded or unhygienic environments through contaminated water, despite its brief survival outside the body.ColonizationOnce ingested, H. pylori enters the stomach and begins colonization by navigating through the mucus layer lining the stomach wall. It...

Gastritis-II: Pathophysiology

Gastritis-II: Pathophysiology

Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...

Genome-wide Association Studies-GWAS

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...

Gastritis-I: Introduction and Types

Gastritis-I: Introduction and Types

Gastritis, defined by the inflammation or irritation of the stomach lining or gastric mucosa, manifests in several distinct forms: acute, chronic, reactive, and a specific subtype known as autoimmune metaplastic atrophic gastritis.
Acute gastritis presents as a sudden inflammation triggered by various stressors to the stomach lining, such as exposure to corrosive agents, local irritants like aspirin and other NSAIDs, alcohol consumption, radiation therapy, physical trauma, severe burns, sepsis,...

Cholecystitis

Cholecystitis

Cholecystitis is inflammation of the gallbladder, most commonly caused by obstruction of the cystic duct. This blockage prevents bile from draining, leading to gallbladder distension, inflammation, and potentially serious complications. This condition may present acutely or chronically and can happen with or without gallstones.EtiologyAbout 95% of cholecystitis cases are calculous, caused by gallstones blocking the cystic duct, leading to bile accumulation and inflammation of the gallbladder...

Gastritis III: Clinical Manifestations and Management

Gastritis III: Clinical Manifestations and Management

The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Letter: Assessing Pruritus Efficacy With Peroxisome Proliferator-Activated Receptor Agonists in Primary Biliary Cholangitis Must Include Grading the Strength of Trial Evidence.

Alimentary pharmacology & therapeutics·2026

Same author

Efficacy and Safety of Nanoencapsulated Sirolimus plus Pegadricase: Results from the Randomized, Placebo-Controlled Phase 3 Trials.

Arthritis & rheumatology (Hoboken, N.J.)·2026

Same author

Reply: Fracture risk under selective and non-selective PPAR agonists in primary biliary cholangitis.

Hepatology communications·2026

Same author

Seladelpar in patients with primary biliary cholangitis and compensated cirrhosis: Efficacy and safety from RESPONSE and ASSURE studies.

Hepatology communications·2026

Same author

Seladelpar Improved Itch, Itch-Related Sleep Disturbance and Measures of Fatigue in Patients With Primary Biliary Cholangitis and Pruritus in the Phase 3 RESPONSE Trial.

Alimentary pharmacology & therapeutics·2026

Same author

Review Article: Targeting Peroxisome Proliferator-Activated Receptors in Primary Biliary Cholangitis.

Alimentary pharmacology & therapeutics·2026

Search research articles

Related Experiment Video

Updated: May 15, 2026

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Published on: March 7, 2025

The year in gout: 2011-2012.

Daria B Crittenden¹, Michael H Pillinger

¹Division of Rheumatology, NYU Hospital for Joint Diseases, New York, NY 10003, USA.

Bulletin of the NYU Hospital for Joint Diseases

|December 25, 2012

Summary

Gout is a growing health concern. Recent scientific and medical advancements have significantly improved our understanding of gout and hyperuricemia in the last 12-18 months.

Area of Science:

Rheumatology
Epidemiology
Internal Medicine

Background:

Gout is a prevalent and increasingly significant clinical issue.
Advances in biology, pharmacology, and imaging have accelerated understanding.
A review of recent progress in gout and hyperuricemia is warranted.

Purpose of the Study:

To summarize key recent advancements in gout research.
To highlight progress in understanding hyperuricemia.
To provide an overview of the last 12-18 months of gout research.

Main Methods:

Literature review of recent studies.
Synthesis of findings from biological, pharmacological, and imaging research.
Focus on developments within the past 12-18 months.

More Related Videos

Tissue Collection and RNA Extraction from the Human Osteoarthritic Knee Joint

Tissue Collection and RNA Extraction from the Human Osteoarthritic Knee Joint

Published on: July 22, 2021

Related Experiment Videos

Last Updated: May 15, 2026

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Published on: March 7, 2025

Tissue Collection and RNA Extraction from the Human Osteoarthritic Knee Joint

Tissue Collection and RNA Extraction from the Human Osteoarthritic Knee Joint

Published on: July 22, 2021

Main Results:

Significant progress has been made in understanding gout and hyperuricemia.
Recent advances span multiple scientific and clinical disciplines.
Key breakthroughs have occurred in the last 1.5 years.

Conclusions:

Our collective understanding of gout has rapidly advanced.
Recent developments offer new insights into hyperuricemia.
The past 12-18 months have been a period of substantial progress in gout research.